Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jaci.2024.07.028 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Eosinophilic Granulomatosis With Polyangiitis: A Real-World Study of Biologics and Sinus Surgery Use for Managing Nasal Polyposis.
Int Forum Allergy Rhinol
January 2025
Department of Otorhinolaryngology, Mayo Clinic in Arizona, Scottsdale, Arizona, USA.
Background/aim: Eosinophilic granulomatosis with polyangiitis (EGPA) is a multisystemic disease associated with nasal polyposis. Multiple biologics are used for managing EGPA, including some approved for nasal polyps (NP). This study investigated real-world biologic prescription patterns for EGPA and their impact on NP and endoscopic sinus surgery (ESS) use.
View Article and Find Full Text PDFTreatment of Severe Asthma: Case Report of Fast Action of Mepolizumab in a Patient with Recent SARS-CoV-2 Infection.
Life (Basel)
August 2024
Department of Woman, Child and of General and Specialized Surgery, University of Campania Luigi Vanvitelli, 80138 Naples, Italy.
Asthma is one of the most common chronic inflammatory diseases of childhood with a heterogeneous impact on health and quality of life. Mepolizumab is an antagonist of interleukin-5, indicated as an adjunct therapy for severe refractory eosinophilic asthma in adolescents and children aged >6 years old. We present the case of a 9 year-old boy with severe asthma who experienced several asthmatic exacerbations following a SARS-CoV-2 infection, necessitating therapy with short-acting bronchodilators, oral corticosteroids, and hospitalization.
View Article and Find Full Text PDFMepolizumab for episodic angioedema with eosinophilia.
J Allergy Clin Immunol
November 2024
Mayo Clinic, Scottsdale, Ariz. Electronic address:
Successful novel use of dupilumab for gastrointestinal involvement of idiopathic hypereosinophilic syndrome: case report and review of the literature.
Clin J Gastroenterol
December 2024
Celiac Disease Program, Vatche and Tamar Manoukian Division of Digestive Diseases, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Article Synopsis
- Hypereosinophilic syndrome (HES) leads to high levels of eosinophils in the blood and tissues, causing organ damage, with gastrointestinal issues being a common manifestation.
- A 28-year-old female patient suffered from severe gastrointestinal symptoms and was diagnosed with idiopathic HES and eosinophilic esophagitis, resistant to multiple treatments.
- After starting dupilumab, a recently FDA-approved treatment, the patient achieved remission, resolving her gastrointestinal issues and allowing her to return to a normal diet without needing total parenteral nutrition.
The standard therapeutic regimen for idiopathic chronic eosinophilic pneumonia (ICEP) involves the administration of oral corticosteroids (OCS). However, a notable proportion of individuals experience recurrent episodes after the tapering or cessation of OCS during the course of ICEP. There has been a growing interest in exploring alternative treatment modalities for patients with ICEP at heightened risk of relapse.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!